Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Videos

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

CancerNetwork - Oncology News and Clinical Expertise

Facebook

LinkedIn

Youtube

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Lenvatinib Plus Pembrolizumab vs Sunitinib in Advanced Renal Cell Carcinoma: Patterns of Progression and  Subsequent Therapy in the CLEAR Trial

Video Series

Metastatic Site–Specific Outcomes With 1L ccRCC Therapies

Panelists discuss how the CLEAR trial highlights the efficacy of lenvatinib plus pembrolizumab over sunitinib in advanced renal cell carcinoma, focusing on patterns of progression and the implications for subsequent therapy.

Panelists discuss how the evolving first-line treatment landscape for advanced renal cell carcinoma is shaped by novel immunotherapy combinations, including lenvatinib plus pembrolizumab, and the impact of these therapies on patient outcomes and progression patterns.

1L Treatment Landscape for Advanced Renal Cell Carcinoma

Panelists discuss how metastatic site–specific outcomes with first-line therapies for clear cell renal cell carcinoma (ccRCC) provide insights into the efficacy of treatment strategies based on the location of metastases.

Panelists discuss how clinical decision-making with TKI-IO combinations for advanced renal cell carcinoma involves evaluating factors such as efficacy, safety, patient characteristics, and the management of treatment-related toxicities to optimize patient outcomes.

Clinical Decision-making With TKI-IO Combinations for Advanced RCC

Panelists discuss how the Phase phase 3 CLEAR trial evaluates organ-specific progression patterns in advanced renal cell carcinoma to better understand the efficacy of lenvatinib plus pembrolizumab compared to with sunitinib and guide subsequent treatment strategies.

Phase 3 CLEAR Trial: Evaluating Organ-Specific Progression Patterns

Panelists discuss time to progression by organ with lenvatinib plus + pembrolizumab in advanced  renal cell carcinoma (RCC), highlighting key data and its the implications for treatment decisions.

Time to Progression by Organ with Lenvatinib Plus + Pembrolizumab in Advanced RCC.

Panelists discuss the follow-up analysis of the CLEAR trial, examining its implications for clinical decision-making in the treatment of advanced  renal cell carcinomaRCC.

CLEAR Follow-Uup Analysis: Implications for Clinical Decision MakingDecision-Making

Panelists discuss future directions in the treatment of advanced  renal cell carcinoma (RCC), focusing on emerging therapies, clinical trials, and potential advancements in patient disease management.

Future Directions in Advanced RCC

Between The Lines

 is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.

Metastatic Site–Specific Outcomes With 1L ccRCC Therapies

EP: 1.1L Treatment Landscape for Advanced Renal Cell Carcinoma

EP: 2.Metastatic Site–Specific Outcomes With 1L ccRCC Therapies

EP: 3.Clinical Decision-making With TKI-IO Combinations for Advanced RCC

EP: 4.Phase 3 CLEAR Trial: Evaluating Organ-Specific Progression Patterns

EP: 5.Time to Progression by Organ with Lenvatinib Plus + Pembrolizumab in Advanced RCC.

EP: 6.CLEAR Follow-Uup Analysis: Implications for Clinical Decision MakingDecision-Making

EP: 7.Future Directions in Advanced RCC